Terms: = Lymphoma AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Prognosis
78 results:
1. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
[TBL] [Abstract] [Full Text] [Related]
2. Epstein-Barr Virus Promotes Tumorigenicity and Worsens Hodgkin lymphoma prognosis by Activating JAK/STAT and NF-κB Signaling Pathways.
Alabiad MA; Said WMM; Saad RHF; Balata R; Mahmoud AA; Metwally EA; Shalaby AM; Samy W; Yehia AM; Yahia AIO; Alorini M; Abdelrahman DI
Iran J Med Sci; 2024 Feb; 49(2):88-100. PubMed ID: 38356485
[TBL] [Abstract] [Full Text] [Related]
3. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.
Tharakan S; Mascarenhas J; Tremblay D
Leuk Lymphoma; 2024 Feb; 65(2):158-167. PubMed ID: 38033130
[No Abstract] [Full Text] [Related]
4. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
[No Abstract] [Full Text] [Related]
5. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
[TBL] [Abstract] [Full Text] [Related]
6. Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.
Li X; Wei Y; Li S; Liang J; Liu Z; Cui Y; Gao J; Yang Z; Li L; Zhou H; Chen S; Yang C
Int Immunopharmacol; 2022 Oct; 111():109138. PubMed ID: 35973369
[TBL] [Abstract] [Full Text] [Related]
7. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
[TBL] [Abstract] [Full Text] [Related]
8. PCM1-jak2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
Kaplan HG; Jin R; Bifulco CB; Scanlan JM; Corwin DR
Oncologist; 2022 Aug; 27(8):e661-e670. PubMed ID: 35472244
[TBL] [Abstract] [Full Text] [Related]
9. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
Sastow D; Mascarenhas J; Tremblay D
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic significance of CRLF2 overexpression and jak2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract] [Full Text] [Related]
11. The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits jak2/STAT3 Pathway in Extranodal NK/T Cell lymphoma.
Xu L; Qin Y; Liu M; Jiao J; Tu D; Zhang M; Yan D; Song X; Sun C; Zhu F; Wang X; Sang W; Xu K
Anticancer Agents Med Chem; 2022; 22(8):1530-1540. PubMed ID: 34503423
[TBL] [Abstract] [Full Text] [Related]
12. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
Lee K; Evans MG; Yang L; Ng S; Snowden C; Khodadoust M; Brown RA; Trum NA; Querfeld C; Doan LT; Song J; Zhang H; Gru AA; Wood GS; Wada DA; Shanmugam V; Haun PL; Aster JC; Duncan LM; Guitart J; Weinstock DM; Nardi V; Choi J
Blood; 2021 Dec; 138(23):2435-2440. PubMed ID: 34432866
[TBL] [Abstract] [Full Text] [Related]
13. Deregulation of jak2 signaling underlies primary cutaneous CD8
Bastidas Torres AN; Cats D; Out-Luiting JJ; Fanoni D; Mei H; Venegoni L; Willemze R; Vermeer MH; Berti E; Tensen CP
Haematologica; 2022 Mar; 107(3):702-714. PubMed ID: 33792220
[TBL] [Abstract] [Full Text] [Related]
14. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract] [Full Text] [Related]
15. Update on CML-Like Disorders.
Cross NCP
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S101-S102. PubMed ID: 32862848
[TBL] [Abstract] [Full Text] [Related]
16. DLBCL with amplification of jak2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
[TBL] [Abstract] [Full Text] [Related]
17. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.
Yumeen S; Mirza FN; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf SR; Surovtseva YV; Foss FM; Girardi M
Blood Adv; 2020 May; 4(10):2213-2226. PubMed ID: 32437546
[TBL] [Abstract] [Full Text] [Related]
18. A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
Sánchez R; Ribera J; Morgades M; Ayala R; Onecha E; Ruiz-Heredia Y; Juárez-Rufián A; de Nicolás R; Sánchez-Pina J; Vives S; Zamora L; Mercadal S; Coll R; Cervera M; García O; Ribera JM; Martínez-López J
Blood Cancer J; 2020 Apr; 10(4):43. PubMed ID: 32332702
[TBL] [Abstract] [Full Text] [Related]
19. The clinical mutatome of core binding factor leukemia.
Opatz S; Bamopoulos SA; Metzeler KH; Herold T; Ksienzyk B; Bräundl K; Tschuri S; Vosberg S; Konstandin NP; Wang C; Hartmann L; Graf A; Krebs S; Blum H; Schneider S; Thiede C; Middeke JM; Stölzel F; Röllig C; Schetelig J; Ehninger G; Krämer A; Braess J; Görlich D; Sauerland MC; Berdel WE; Wörmann BJ; Hiddemann W; Spiekermann K; Bohlander SK; Greif PA
Leukemia; 2020 Jun; 34(6):1553-1562. PubMed ID: 31896782
[TBL] [Abstract] [Full Text] [Related]
20. Identification of RNPC3 as a novel jak2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract] [Full Text] [Related]
[Next]
